Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), C/ Sant Antoni Maria Claret N° 167. Pavelló 18, 08025, Barcelona, Spain.
Universitat Autònoma Barcelona, Barcelona, Spain.
Clin Transl Oncol. 2022 Aug;24(8):1588-1604. doi: 10.1007/s12094-022-02807-w. Epub 2022 Mar 14.
To assess the methodological quality of all relevant and recent European clinical practice guidelines (CPGs) for advanced oesophageal and gastric cancers, and to synthesise their recommendations on the use of chemotherapy.
We searched PubMed, EMBASE, guidelines repositories, and other sources from 2010 onwards. We appraised quality using AGREE-II and AGREE-REX.
11 CPGs were included (five high, five low, and one moderate quality). Most guidelines showed deficiencies in the domain "applicability", with only three scoring above 60%. Nine did not report having sought the views and preferences of the target population. The lowest scores for AGREE-REX were item Values and Preferences of Target Users (1.6; SD 1.3), and item Values and Preferences of Policy/Decision-Makers (1.8; SD 1.7). The domain Clinical Applicability got the highest score and the domain Implementability got the lowest.
An urgent area of research is how to develop credible and implementable recommendations on the clinical use of CT for advanced oesophageal and gastric cancer.
PROSPERO (CRD42021236753).
评估所有最新的欧洲关于晚期食管和胃癌症的临床实践指南（CPGs）的方法学质量，并综合其关于化疗使用的建议。
我们从 2010 年起在 PubMed、EMBASE、指南库和其他来源中进行了检索。我们使用 AGREE-II 和 AGREE-REX 来评估质量。
纳入了 11 项 CPG（5 项高质量、5 项低质量和 1 项中质量）。大多数指南在“适用性”领域存在缺陷，只有 3 项得分超过 60%。9 项没有报告征求目标人群的意见和偏好。AGREE-REX 中得分最低的项目是目标用户的价值观和偏好（1.6；SD 1.3）和政策/决策者的价值观和偏好（1.8；SD 1.7）。临床适用性领域得分最高，可操作性领域得分最低。
一个紧迫的研究领域是如何制定关于晚期食管和胃癌症 CT 临床应用的可信和可实施的建议。
PROSPERO（CRD42021236753）。
